Biological Products, (No Diagnostic Substances) · L3 · CIK 1638097
Develops first-in-class oral tablet peptide therapies for chronic conditions
Comparable business profile · signals at a glance
In the 90 days to Mar 9, 2026: 5 insiders bought $141K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 | Germano Geno JDirector | Buy | 20,000 | $1.30 | $26K |
| Mar 5, 2026 | Ellis SeanDirector | Buy | 10,000 | $1.23 | $12K |
| Feb 12, 2026 | Rubin Steven DDirector | Buy | 5,000 | $1.49 | $7K |
| Feb 10, 2026 | Germano Geno JDirector | Buy | 20,000 | $1.49 | $30K |
| Feb 10, 2026 | Taitel HayaDirector | Buy | 7,500 | $1.48 | $11K |
| Feb 9, 2026 | Ellis SeanDirector | Buy | 18,000 | $1.24 | $22K |
| Feb 9, 2026 | Rubin Steven DDirector | Buy | 10,000 | $1.20 | $12K |
| Dec 29, 2025 | Toledano Miranda JayneChief Executive Officer | Buy | 11,000 | $1.81 | $20K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.